newsfilter
← Latest News
GlobeNewswire·

Resmed Inc. Announces Results for the First Quarter of Fiscal Year 2027

RMD
  • ResMed reported Q1 2027 revenue of $1.4 billion, an increase of 6% year-over-year or 7% on a core constant currency basis.
  • GAAP diluted earnings per share rose 23% to $2.92, while non-GAAP diluted earnings per share increased 14% to $2.91.
  • The company returned over $1.0 billion to shareholders during the quarter through share repurchases & dividends.
  • ResMed closed the previously announced divestiture of its MatrixCare business.
  • The U.S. launch of the AirTouch F40 fabric CPAP mask was announced as a new product addition.
  • A partnership with Eight Sleep was established to integrate technology with ResMed sleep insights in the U.S. & Australia.
  • ResMed partnered with NASCAR driver Tyler Reddick to raise awareness regarding sleep apnea diagnosis & treatment.
  • Carol Burt was appointed as Lead Director effective November 15, 2026, following the retirement of Director Ron Taylor.
  • Fiscal year 2027 guidance remains unchanged, projecting core constant currency revenue growth of 5-7% & non-GAAP diluted EPS between $12.00 & $12.25.
  • The board declared a quarterly cash dividend of $0.66 per share with a record date of November 12, 2026, & payment date of December 17, 2026.
  • Non-GAAP gross margin expanded 50 basis points to 62.5% due to productivity pipeline execution.
  • Operating cash flow totaled $422 million, while free cash flow reached $374 million for the quarter.
  • Residential Care Software revenue decreased 7% overall but increased 8% after excluding the divested MatrixCare business.
  • Americas Sleep & Breathing Health revenue grew 7% on a core constant currency basis, while Rest of World grew 8%.
  • ResMed revised the presentation of restructuring expenses & amortization of acquired intangibles to align with cost functions.